Weiwei Tang (Tang Weiwei)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 31

Top Topics

Signaling Pathway

Top Venues

Cell death & disease

Journal for immunotherapy of cancer

Journal of oncology

Signal transduction and targeted therapy

This page only lists publications with an associated author ORCID identifier.

Publications

Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Muxin Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, Shuli Zhao
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer. Cell death & disease 15 (2) (2024)
Tian Huang, Hengsong Cao, Chuan Liu, Xiaohu Sun, Shipeng Dai, Li Liu, Yuliang Wang, Cheng Guo, Xue-Hao Wang, Yun Gao, Weiwei Tang, Yongxiang Xia
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell death & disease 15 (6) (2024)
Tian Huang, Hengsong Cao, Chuan Liu, Xiaohu Sun, Shipeng Dai, Li Liu, Yuliang Wang, Cheng Guo, Xue-Hao Wang, Yun Gao, Weiwei Tang, Yongxiang Xia
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell death & disease 15 (6) (2024)
Xiaoli Shi, Xinyi Wang, Wentao Yao, Dongmin Shi, Xihuan Shao, Zhengqing Lu, Yue Chai, Jinhua Song, Weiwei Tang, Xue-Hao Wang
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal transduction and targeted therapy 9 (1) (2024)
Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Muxin Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, Shuli Zhao
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer. Cell death & disease 15 (2) (2024)
Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Muxin Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, Shuli Zhao
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer. Cell death & disease 15 (2) (2024)
Hanyuan Liu, Xiao Li, Chenwei Zhang, Xiaopei Hao, Yongfang Cao, Yuliang Wang, Hao Zhuang, Na Yu, Tian Huang, Chuan Liu, Hengsong Cao, Zhengqing Lu, Jinhua Song, Li Liu, Hanjin Wang, Zhouxiao Li, Weiwei Tang
GJB2 Promotes HCC Progression by Activating Glycolysis Through Cytoplasmic Translocation and Generating a Suppressive Tumor Microenvironment Based on Single Cell RNA Sequencing. Advanced science (Weinheim, Baden-Wurttemberg, Germany) (2024)
Xiaoli Shi, Xinyi Wang, Wentao Yao, Dongmin Shi, Xihuan Shao, Zhengqing Lu, Yue Chai, Jinhua Song, Weiwei Tang, Xue-Hao Wang
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal transduction and targeted therapy 9 (1) (2024)
Tian Huang, Hengsong Cao, Chuan Liu, Xiaohu Sun, Shipeng Dai, Li Liu, Yuliang Wang, Cheng Guo, Xue-Hao Wang, Yun Gao, Weiwei Tang, Yongxiang Xia
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell death & disease 15 (6) (2024)
Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Muxin Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, Shuli Zhao
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer. Cell death & disease 15 (2) (2024)
Xiaoli Shi, Xinyi Wang, Wentao Yao, Dongmin Shi, Xihuan Shao, Zhengqing Lu, Yue Chai, Jinhua Song, Weiwei Tang, Xue-Hao Wang
Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives. Signal transduction and targeted therapy 9 (1) (2024)
Tian Huang, Hengsong Cao, Chuan Liu, Xiaohu Sun, Shipeng Dai, Li Liu, Yuliang Wang, Cheng Guo, Xue-Hao Wang, Yun Gao, Weiwei Tang, Yongxiang Xia
MAL2 reprograms lipid metabolism in intrahepatic cholangiocarcinoma via EGFR/SREBP-1 pathway based on single-cell RNA sequencing. Cell death & disease 15 (6) (2024)
Haiyang Li, Na Zheng, Anning Guo, Weiwei Tang, Muxin Li, Yuanyuan Cao, Xinhua Ma, Hongyong Cao, Yong Ma, Hanjin Wang, Shuli Zhao
FSTL3 promotes tumor immune evasion and attenuates response to anti-PD1 therapy by stabilizing c-Myc in colorectal cancer. Cell death & disease 15 (2) (2024)
Weiwei Tang, Guangshun Sun, Gu-Wei Ji, Tingting Feng, Qian Zhang, Hengsong Cao, Wenhao Wu, Xiaoyi Zhang, Chuan Liu, Hanyuan Liu, Tian Huang, Li Liu, Yongxiang Xia, Xuehao Wang
Single-cell RNA-sequencing atlas reveals an FABP1-dependent immunosuppressive environment in hepatocellular carcinoma. Journal for immunotherapy of cancer 11 (11) (2023)
Guangshun Sun, Siqi Zhao, Zhongguo Fan, Yuliang Wang, Hanyuan Liu, Hengsong Cao, Guoqiang Sun, Tian Huang, Hongzhou Cai, Hong Pan, Dawei Rong, Yun Gao, Weiwei Tang
CHSY1 promotes CD8 + T cell exhaustion through activation of succinate metabolism pathway leading to colorectal cancer liver metastasis based on CRISPR/Cas9 screening. Journal of experimental & clinical cancer research : CR 42 (1) (2023)
Weiwei Tang, Hanyuan Liu, Xiao Li, Theng Choon Ooi, Nor Fadilah Rajab, Hongyong Cao, Razinah Sharif
Upregulation of APOC1 Promotes Colorectal Cancer Progression and Serves as a Potential Therapeutic Target Based on Bioinformatics Analysis. Journal of oncology 2023 (2023)
Guangshun Sun, Hanyuan Liu, Jie Zhao, Jinyu Zhang, Tian Huang, Guoqiang Sun, Siqi Zhao, Zihao Zhang, Hengsong Cao, Dawei Rong, Xiangyi Kong, Qinghua Ji, Li Liu, Xuehao Wang, Weiwei Tang, Yongxiang Xia
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. Journal for immunotherapy of cancer 10 (12) (2023)
Dawei Rong, Yuliang Wang, Li Liu, Hengsong Cao, Tian Huang, Hanyuan Liu, Xiaopei Hao, Guangshun Sun, Guoqiang Sun, Zhiying Zheng, Junwei Kang, Yongxiang Xia, Ziyi Chen, Weiwei Tang, Xuehao Wang
GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway. Journal for immunotherapy of cancer 11 (2) (2023)
Weiwei Tang, Hanyuan Liu, Xiao Li, Theng Choon Ooi, Nor Fadilah Rajab, Hongyong Cao, Razinah Sharif
Upregulation of APOC1 Promotes Colorectal Cancer Progression and Serves as a Potential Therapeutic Target Based on Bioinformatics Analysis. Journal of oncology 2023 (2023)
Guangshun Sun, Hanyuan Liu, Jie Zhao, Jinyu Zhang, Tian Huang, Guoqiang Sun, Siqi Zhao, Zihao Zhang, Hengsong Cao, Dawei Rong, Xiangyi Kong, Qinghua Ji, Li Liu, Xuehao Wang, Weiwei Tang, Yongxiang Xia
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. Journal for immunotherapy of cancer 10 (12) (2023)
Dawei Rong, Yuliang Wang, Li Liu, Hengsong Cao, Tian Huang, Hanyuan Liu, Xiaopei Hao, Guangshun Sun, Guoqiang Sun, Zhiying Zheng, Junwei Kang, Yongxiang Xia, Ziyi Chen, Weiwei Tang, Xuehao Wang
GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway. Journal for immunotherapy of cancer 11 (2) (2023)
Dawei Rong, Yuliang Wang, Li Liu, Hengsong Cao, Tian Huang, Hanyuan Liu, Xiaopei Hao, Guangshun Sun, Guoqiang Sun, Zhiying Zheng, Junwei Kang, Yongxiang Xia, Ziyi Chen, Weiwei Tang, Xuehao Wang
GLIS1 intervention enhances anti-PD1 therapy for hepatocellular carcinoma by targeting SGK1-STAT3-PD1 pathway. Journal for immunotherapy of cancer 11 (2) (2023)
Guangshun Sun, Hanyuan Liu, Jie Zhao, Jinyu Zhang, Tian Huang, Guoqiang Sun, Siqi Zhao, Zihao Zhang, Hengsong Cao, Dawei Rong, Xiangyi Kong, Qinghua Ji, Li Liu, Xuehao Wang, Weiwei Tang, Yongxiang Xia
Macrophage GSK3β-deficiency inhibits the progression of hepatocellular carcinoma and enhances the sensitivity of anti-PD1 immunotherapy. Journal for immunotherapy of cancer 10 (12) (2023)
Xiao Li, Liangliang Wu, Zhiying Zheng, Hanyuan Liu, Haiyang Li, Guoqiang Sun, Guangshun Sun, Ye Cheng, Hanjin Wang, Zhouxiao Li, Junfeng Shi, Weiwei Tang
Tegaserod Maleate Inhibits Breast Cancer Progression and Enhances the Sensitivity of Immunotherapy. Journal of oncology 2022 (2022)
Sun Guangshun, Sun Guoqiang, Chen Xin, Kong Xiangyi, Zheng Wubin, Li Zhitao, Zheng Zhiying, Hongyong Cao, Lv Chengyu, Yongxiang Xia, Weiwei Tang
Meloxicam Inhibits Hepatocellular Carcinoma Progression and Enhances the Sensitivity of Immunotherapy via the MicroRNA-200/PD-L1 Pathway. Journal of oncology 2022 (2022)
Guoqiang Sun, Ganggang Miao, Zhitao Li, Wubin Zheng, Chunguang Zhou, Guangshun Sun, Hongyong Cao, Zhouxiao Li, Weiwei Tang
Inhibition of PARP Potentiates Immune Checkpoint Therapy through miR-513/PD-L1 Pathway in Hepatocellular Carcinoma. Journal of oncology 2022 (2022)
Yongxiang Xia, Weiwei Tang, Xiaofeng Qian, Xiangcheng Li, Feng Cheng, Ke Wang, Feng Zhang, Chuanyong Zhang, Donghua Li, Jinhua Song, Hui Zhang, Jie Zhao, Aihua Yao, Xiaofeng Wu, Chen Wu, Gu-Wei Ji, Xisheng Liu, Feipeng Zhu, Lang Qin, Xuan Xiao, Zhenhua Deng, Xiangyi Kong, Si Li, Yangyang Yu, Wenjing Xi, Wanglong Deng, Chuang Qi, Hanyuan Liu, Liyong Pu, Ping Wang, Xuehao Wang
Efficacy and safety of camrelizumab plus apatinib during the perioperative period in resectable hepatocellular carcinoma: a single-arm, open label, phase II clinical trial. Journal for immunotherapy of cancer 10 (4) (2022)
Xiaopei Hao, Yao Zhang, Xiaoli Shi, Hanyuan Liu, Zhiying Zheng, Guoyong Han, Dawei Rong, Chuanyong Zhang, Weiwei Tang, Xuehao Wang
CircPAK1 promotes the progression of hepatocellular carcinoma via modulation of YAP nucleus localization by interacting with 14-3-3ζ. Journal of experimental & clinical cancer research : CR 41 (1) (2022)
Xiao Li, Guangshun Sun, Liangliang Wu, Guoqiang Sun, Ye Cheng, Jing Tao, Zhouxiao Li, Weiwei Tang, Hanjin Wang
Upregulation of ADAR Promotes Breast Cancer Progression and Serves as a Potential Therapeutic Target. Journal of oncology 2021 (2021)
Chen Lu, Dawei Rong, Bingqing Hui, Xuezhi He, Wei Jiang, Yetao Xu, Hongyong Cao, Ze-Kuan Xu, Weiwei Tang
CircETFA upregulates CCL5 by sponging miR-612 and recruiting EIF4A3 to promote hepatocellular carcinoma. Cell death discovery 7 (1) (2021)
Jin Xu, Junfeng Shi, Weiwei Tang, Peng Jiang, Muhong Guo, Bin Zhang, Ge Ma
ROR2 promotes the epithelial-mesenchymal transition by regulating MAPK/p38 signaling pathway in breast cancer. Journal of cellular biochemistry 121 (10) (2020)